Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Ward

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
BMJ (Clinical Research Ed.)|July 20, 2022
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELYWilliam J Hulme, Elizabeth J Williamson, Amelia C A Green, et al.
Wellcome Open Research|May 31, 2022
A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data ReportAnna Rowan, Chris Bates, William Hulme, et al.
The Lancet. Rheumatology|June 14, 2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platformBrian MacKenna, Nicholas A Kennedy, Amir Mehrkar, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
BMJ (Clinical Research Ed.)|July 20, 2022
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELYWilliam J Hulme, Elizabeth J Williamson, Amelia C A Green, et al.
Wellcome Open Research|May 31, 2022
A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data ReportAnna Rowan, Chris Bates, William Hulme, et al.
The Lancet. Rheumatology|June 14, 2022
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platformBrian MacKenna, Nicholas A Kennedy, Amir Mehrkar, et al.
Pageof 5